A new generation of high-affinity humanized PEGylated Fab´´ fragment anti-tumor necrosis factor-αα monoclonal antibodies

Author： Weir Neil   Athwal Dee   Brown Derek   Foulkes Roly   Kollias George   Nesbitt Andrew   Popplewell Andy   Spitali Mari   Stephens Sue  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.3, Iss.4, 2006-07, pp. : 535-545

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recalcitrant psoriatic uveitis and anti‐tumor necrosis factor‐α monoclonal antibodies: experience from a psoriasis referral center

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 9, 2015-09 ,pp. : 1105-1108

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 8, 2015-05 ,pp. : 2011-2019

John Wiley & Sons Inc

Access to resources Recommend Favorite

The risk of tuberculosis in patients with psoriasis treated with anti‐tumor necrosis factor agents

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : 594-599

John Wiley & Sons Inc

Access to resources Recommend Favorite

Minimal Disease Activity and Anti–Tumor Necrosis Factor Therapy in Psoriatic Arthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 6, 2015-05 ,pp. : 842-847

John Wiley & Sons Inc

Access to resources Recommend Favorite

Exploring conditions for redistribution of anti‐tumor necrosis factors to reduce spillage: A study on the quality of anti‐tumor necrosis factor home storage

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 2, 2018-02 ,pp. : 426-430

John Wiley & Sons Inc

Access to resources Recommend Favorite